PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications

Background Despite significant advances in molecular characterization and therapeutic targeting of advanced prostate cancer, it remains the second most common cause of cancer death in men in the United States. The PI3K (Phosphatidylinositol 3‐kinase)/AKT (AKT serine/threonine kinase)/mTOR (mammalian...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Prostate Jg. 82; H. S1; S. S60 - S72
1. Verfasser:	Choudhury, Atish D.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Wiley Subscription Services, Inc 01.08.2022
Schlagworte:	1-Phosphatidylinositol 3-kinase AKT AKT protein Biomarkers capivasertib Cell migration Cell proliferation Cell survival Clinical trials Humans Immune checkpoint inhibitors ipatasertib Kinases LY3023414 Male mTOR Phosphatidylinositol 3-Kinases - metabolism PI3K PIK3CA Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Prostate cancer Prostatic Neoplasms - drug therapy Protein-serine/threonine kinase Proto-Oncogene Proteins c-akt - metabolism PTEN PTEN Phosphohydrolase - metabolism PTEN protein Rapamycin Ribose samotolisib Signal Transduction Tensin Therapeutic targets TOR protein TOR Serine-Threonine Kinases - metabolism Tumor suppressor genes Tumors prostate cancer samotolisib LY3023414 PI3K PIK3CA ipatasertib PTEN mTOR capivasertib AKT
ISSN:	0270-4137, 1097-0045, 1097-0045
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!